Trade Summary

3 days ago, Aballi John, serving as Pres, CEO at Exagen Inc. (XGN), sold 11,430 shares at $3.61 per share, for a total transaction value of $41,262.00. Following this transaction, Aballi John now holds 743,398 shares of XGN.

This sale represents a 2.00% decrease in Aballi John's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, February 24, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 25, 2026, 1 day after the trade was made.

Exagen Inc. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.